Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Edaravone Extension Study in ALS
NCT05568615Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of edaravone in amyotrophic lateral sclerosis (ALS), sponsored by Shionogi & Co., Ltd. Primary endpoint: Adverse Events at 8 months. Started Oct 2022; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05568615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05568615.